

MMHCC Newsletter May 2009

MouseLine

KOMP Repository

By Kent Lloyd

The Knockout Mouse Project (KOMP) is now well on its way to generating a comprehensive and public resource comprised of mouse embryonic stem (ES) cells containing null and conditional-ready mutations in every gene in the mouse genome. Sponsored by nineteen institutes of the NIH, the KOMP Program is generating this superb collection in the C57BL/6N genetic background. As of today, more than 9315 ES cell clones representing 1696 unique target genes have been released for distribution, including targeted ES cells with mutations in Rnf6 (esophageal cancer), Mllt10 (AML), Dirc2 (renal carcinoma), Opcm1 (ovarian-breast cancer), Armet (pancreatic cancer), Prcc (renal cell papillary carcinoma). ES cell clones, vectors, germplasm and mice can all be obtained by going to the KOMP Repository. There you can also see what's coming to the repository in the near future, what is being targeted by the KOMP production teams, even access to vector designs and genes in the pipeline! Check it out...go to http://www.komp.org and browse our catalog (now with new advanced search capabilities), search our database for your favorite gene, create a user account so you can register interest in a gene target and we'll notify you when it's ready, or nominate a gene for the KOMP Production Teams to target. For customer support, send an email to service@komp.org, or call us at 1-888-KOMP-MICE.

Links:

KOMP Project on NIH Website: http://www.nih.gov/science/models/mouse/knockout/

KOMP Repository: http://www.komp.org

Browse KOMP Catalog: http://www.komp.org/catalog.php

Search KOMP Database: http://www.komp.org/advancedSearch.php
Create KOMP User Account: http://www.komp.org/register.php

Nominate Gene: http://www.informatics.jax.org/mgihome/KOMP/nominationForm.shtml







Meetings

May 27 - 29, 2009

CHI's - Biomarker World Congress

Philadelphia, Pennsylvania

Meeting Information: http://www.biomarkerworldcongress.com/

June 1 - 3, 2009

CHI's-Protein Kinase Targets: Discovery and Design for Success

Cambridge, Massachusetts

Meeting Information: http://www.healthtech.com/KIN

June 8 - 10, 2009

CHI's-Genomic Tools & Technologies & RNA Interference Summit

San Francisco, California

Meeting Information: http://www.healthtech.com/gta/gtl

June 11 - 13, 2009

Colony Management: Principles and Practices, at Emory University

Atlanta, Georgia

Meeting Information: http://courses.jax.org/2009/colony_emory.html

June 17 - 19, 2009

AACR-Accelerating Anticancer Agent Development and Validation Workshop

North Bethesda, Maryland

Meeting Information: http://www.acceleratingworkshop.org/

June 20 - 26, 2009

AACR-Methods in Clinical Cancer Research (Europe)

Flims, Switzerland

Meeting Information: http://www.ecco-org.eu/Education/ECCO-Education/Flims/FLIMS-10/page.aspx/414

June 21 - 26, 2009

AACR-Cancer Research Imaging Camp

St. Louis, Missouri

Meeting Information: http://imaging.cancer.gov/NewsAndMeetings/workshops/CRIC

June 21 - 26, 2009

Comprehensive Approaches to the in vivo Assessment of Cardiovascular Function in Mice

Bar Harbor, ME

Meeting Information: http://courses.jax.org/2009/cardio-09.html







Notices and Funding Opportunities

To receive up-to-date information on ARRA (American Recovery and Reinvestment Funding) opportunities, visit:

http://grants.nih.gov/recovery/ and http://www.nih.gov/recovery/

SCAW IACUC-Advanced Workshop: June 15, 2009 in Research Triangle Park, NC

NOT-OD-09-081

National Institutes of Health

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-081.html

IACUC 101 and 201 PLUS Workshops: June 24-25, 2009 in Niagara Falls, NY

NOT-OD-09-089

National Institutes of Health

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-089.html

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (P01)

PAR-09-147

National Cancer Institute

http://grants.nih.gov/grants/guide/pa-files/PAR-09-147.html

In vivo Cellular and Molecular Imaging Centers (ICMICs) (P50)

PAR-09-157

National Cancer Institute

http://grants.nih.gov/grants/guide/pa-files/PAR-09-157.html

Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21)

PAR-09-160

National Cancer Institute

http://grants.nih.gov/grants/guide/pa-files/PAR-09-160.html

Basic Cancer Research in Cancer Health Disparities (U01)

PAR-09-161

National Cancer Institute

http://grants.nih.gov/grants/guide/pa-files/PAR-09-161.html







2009 caBIG® Annual Conference

The 2009 Annual caBIG[®] Conference will convene on July 20 – 22, 2009 at the Marriott Wardman Park Hotel in Washington, D.C. The conference is titled "Solving Basic and Clinical Research Challenges in Cancer and Beyond."

Attendees will hear how caBIG® is accelerating biomedical research through interoperable tools, infrastructure, standards, and policies that enable data-sharing and collaborations that transcend institutional, geographical, and disciplinary boundaries.

The meeting will feature:

- Case studies and best practices in clinical trials management, *in vivo* imaging, molecular analysis, tissue banking and pathology, and data-sharing and security
- Tips on implementing, adapting, and customizing caBIG[®] tools and infrastructure
- Presentations on caBIG®-enabled translational research projects in cancer and beyond
- Opportunities for future collaborations and partnerships

Multiple tracks of presentations will cover a variety of topics in basic, clinical and translational research. Separate tracks of technical presentations discuss the implementation of caBIG[®] tools and adaptation of existing tools to become caBIG[®] -compatible.

Please visit the website for detailed information and to register for this exciting meeting: https://cabig.nci.nih.gov/2009AnnualMeeting

What's new in caMOD

The following models have been approved for public display since March 1, 2009. Visit http://cancermodels.nci.nih.gov to learn more about these new models.

Model UID	Model Descriptor	Species
	Electrochemotherapy treatment of feline squamous cell	
<u>50060072</u>	carcinoma	Cat
	Use of a liposomal cisplatin analogue in feline oral	
<u>50060979</u>	squamous cell carcinoma.	Cat
	Phase I study of melphalan alone and melphalan plus	
	whole body hyperthermia < br > in dogs with malignant	
50058683	melanoma	Dog
	Effect of timing of postoperative chemotherapy on survival	
<u>50060581</u>	of dogs with osteosarcoma	Dog
	Results of surgery and doxorubicin chemotherapy in dogs	
50060625	with osteosarcoma	Dog
	Response of canine osteosarcoma to treatment by	· ·
	amputation versus amputation br>and adjuvant	
50060669	chemotherapy using doxorubicin and cisplatin	Dog









50060870	L-MTP-PE and cisplatin treatment of canine osteosarcoma	Dog
<u>50060921</u>	Localized thermo-cisplatin therapy in dogs	Dog
<u>50061032</u>	Paclitaxel (Taxol) treatment of canine malignant tumors	Dog
	Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in	
<u>50061083</u>	dogs with spontaneous neoplasia	Dog
	Thermal ablation of the goat mammary gland as a model	
50060892	for post-lumpectomy treatment of breast cancer	Goat
	Cisplatin-containing biodegradable beads in equine	
50060944	cutaneous neoplasia	Horse
	Intratumoral cisplatin in sesame oil emulsion in equine	
<u>50061004</u>	cutaneous tumors	Horse

Disclaimer

NCI does not endorse or recommend any commercial products, processes, or services described in this newsletter, or in any "off-site" external link web pages referenced in this newsletter or in the NCI emice website. The views and opinions of authors expressed in this newsletter do not necessarily state or reflect those of the United States Government and they may not be used for advertising or product endorsement purposes. Further, this newsletter is intended for informational purposes only. NCI does not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed. NCI makes no warranties, either express or implied; including the warranties of merchantability or fitness for a particular purpose or that the use of this software or data will not infringe any third party patents, copyrights, trademark, or other rights.



